Eli Lilly's Taltz and Zepbound Show Remarkable Efficacy in Psoriatic Arthritis Treatment
Recent findings from the Phase 3b clinical trial, TOGETHER-PsA, have unveiled significant progress in treating adults suffering from psoriatic arthritis and obesity. Conducted by Eli Lilly and Company, this innovative study specifically examined the combined use of Taltz (ixekizumab) and Zepbound (tirzepatide), comparing these treatments with Taltz alone. The results indicate that the dual treatment effectively amplified patient improvements in disease control and overall metabolic health over a year.
In the trial, nearly three times the number of patients utilizing both Taltz and Zepbound experienced a substantial reduction in psoriatic arthritis disease activity, measured by the ACR50 criteria, compared to those receiving Taltz as a standalone treatment. Notably, at the one-year mark, 43.7% of participants on the dual therapy achieved the ACR50, in stark contrast to just 15.7% in the Taltz-only group. This pronounced effectiveness underscores the therapeutic potential of a combined approach for individuals battling the complexities associated with both arthritis and obesity.
The TOGETHER-PsA study, presented at the American College of Rheumatology (ACR) Convergence 2026 and subsequently published in Arthritis & Rheumatology, also reported significant improvements in patient-reported outcomes. Measures such as physical function and fatigue levels were enhanced in participants receiving the combined treatment from Week 36 through to Week 52.
Moreover, those on the Taltz and Zepbound regimen exhibited favorable changes in several metabolic markers, including reduced body mass index (BMI), body weight, and levels of glucose, triglycerides, and total cholesterol. These findings are especially vital, considering that approximately 65% of individuals with psoriatic arthritis also present with obesity or weight-related health complications, complicating treatment outcomes.
Dr. Mark Genovese, a key figure in Lilly's Immunology development, highlighted the significance of these findings, noting the durable efficacy and improved quality of life for patients taking Taltz and Zepbound together. This combined treatment approach presents a new framework for managing the intersecting challenges of psoriatic arthritis and metabolic dysfunction, embracing a holistic view of patient health.
PSA, as an inflammatory immune-mediated condition, can severely impact a patient's quality of life. Medical experts strongly recommend addressing the coexistence of obesity, as it plays a critical role in exacerbating treatment difficulties. The TOGETHER-PsA study’s findings reinforce the strategic importance of considering dual therapy to mitigate the combined health burdens these patients experience.
One of the pivotal observations from the trial, which involved a comprehensive participant pool of 271 individuals, is that treatment success began to manifest as early as four weeks into the regimen. This early improvement is noteworthy in the context of concurrent weight loss, which became apparent later.
The safety profile of using Taltz and Zepbound in conjunction remained consistent with expectations for both medications. Side effects were largely mild to moderate, with the most common adverse reactions including gastrointestinal issues like nausea, diarrhea, and injection site reactions. Continuous monitoring and patient education remain paramount in the administration of these therapies.
In summation, the TOGETHER-PsA trial not only establishes the compelling effectiveness of combining Taltz and Zepbound but also signifies a step forward in the clinical approach to treating psoriatic arthritis compounded by obesity. As the medical community advances its understanding of concurrent chronic conditions, Eli Lilly's innovations illuminate pathways for future therapeutic strategies aimed at enhancing patient outcomes and transforming lives.
In the trial, nearly three times the number of patients utilizing both Taltz and Zepbound experienced a substantial reduction in psoriatic arthritis disease activity, measured by the ACR50 criteria, compared to those receiving Taltz as a standalone treatment. Notably, at the one-year mark, 43.7% of participants on the dual therapy achieved the ACR50, in stark contrast to just 15.7% in the Taltz-only group. This pronounced effectiveness underscores the therapeutic potential of a combined approach for individuals battling the complexities associated with both arthritis and obesity.
The TOGETHER-PsA study, presented at the American College of Rheumatology (ACR) Convergence 2026 and subsequently published in Arthritis & Rheumatology, also reported significant improvements in patient-reported outcomes. Measures such as physical function and fatigue levels were enhanced in participants receiving the combined treatment from Week 36 through to Week 52.
Moreover, those on the Taltz and Zepbound regimen exhibited favorable changes in several metabolic markers, including reduced body mass index (BMI), body weight, and levels of glucose, triglycerides, and total cholesterol. These findings are especially vital, considering that approximately 65% of individuals with psoriatic arthritis also present with obesity or weight-related health complications, complicating treatment outcomes.
Dr. Mark Genovese, a key figure in Lilly's Immunology development, highlighted the significance of these findings, noting the durable efficacy and improved quality of life for patients taking Taltz and Zepbound together. This combined treatment approach presents a new framework for managing the intersecting challenges of psoriatic arthritis and metabolic dysfunction, embracing a holistic view of patient health.
PSA, as an inflammatory immune-mediated condition, can severely impact a patient's quality of life. Medical experts strongly recommend addressing the coexistence of obesity, as it plays a critical role in exacerbating treatment difficulties. The TOGETHER-PsA study’s findings reinforce the strategic importance of considering dual therapy to mitigate the combined health burdens these patients experience.
One of the pivotal observations from the trial, which involved a comprehensive participant pool of 271 individuals, is that treatment success began to manifest as early as four weeks into the regimen. This early improvement is noteworthy in the context of concurrent weight loss, which became apparent later.
The safety profile of using Taltz and Zepbound in conjunction remained consistent with expectations for both medications. Side effects were largely mild to moderate, with the most common adverse reactions including gastrointestinal issues like nausea, diarrhea, and injection site reactions. Continuous monitoring and patient education remain paramount in the administration of these therapies.
In summation, the TOGETHER-PsA trial not only establishes the compelling effectiveness of combining Taltz and Zepbound but also signifies a step forward in the clinical approach to treating psoriatic arthritis compounded by obesity. As the medical community advances its understanding of concurrent chronic conditions, Eli Lilly's innovations illuminate pathways for future therapeutic strategies aimed at enhancing patient outcomes and transforming lives.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.